Kiin Bio Raises $2.2M Pre-Seed to Build AI Platform of "Virtual Scientists" for Drug Discovery

Kiin Bio, a 2024-founded startup developing an AI-native research platform for drug discovery, has raised $2.2 million in pre-seed funding led by b2venture. The company’s platform deploys “Virtual Scientists”—generative AI agents designed to plan, analyze, and orchestrate experiments across lab data, modeling tools, and analysis pipelines. Rather than replacing workflows, Kiin integrates with tools already used by R&D teams, aiming to increase output without requiring additional human hires.

The platform aims to target inefficiencies in pharma R&D, where siloed systems and manual processes reduce the effectiveness of AI adoption. Kiin’s approach addresses this by operating end-to-end, from hypothesis generation to experimental execution, and is structured to learn from interaction metadata (experiment plans, troubleshooting steps, and outcome histories) creating a proprietary reasoning loop that grows over time.

Kiin Bio founders: Mark Davies, Filippo Abbondanza and Bogdan Urse; Source: b2venture

Kiin licenses access on a per-agent basis, allowing smaller biotech teams to scale capacity without high upfront costs. Additional tools, models, and data can be accessed via a marketplace with transparent pricing. The system is designed to support future lab automation, positioning Kiin as a control layer for vertically integrated discovery workflows.

The founding team includes CEO Filippo Abbondanza (PhD, bioinformatics; ex-Lifebit), CDSO Mark Davies (ex-BenevolentAI), and CTO Bogdan Urse (infrastructure lead at Lifebit). Kiin is currently partnering with biotech and academic labs to refine its platform and is onboarding additional data and tooling providers to expand its ecosystem.

Topics: Startups & Deals